Mao Benliang, Yuan Wei, Wu Fan, Yan Yong, Wang Bailin
Department of General Surgery, Guangzhou Red Cross Hospital affiliated to Jinan University, Guangzhou, China.
College of Clinical Medicine, Guizhou Medical University, Guiyang, China.
Cell Death Discov. 2023 Apr 5;9(1):115. doi: 10.1038/s41420-023-01387-0.
Hepatic ischemia-reperfusion injury (HIRI) is a major complication of liver resection or liver transplantation that can seriously affect patient's prognosis. There is currently no definitive and effective treatment strategy for HIRI. Autophagy is an intracellular self-digestion pathway initiated to remove damaged organelles and proteins, which maintains cell survival, differentiation, and homeostasis. Recent studies have shown that autophagy is involved in the regulation of HIRI. Numerous drugs and treatments can change the outcome of HIRI by controlling the pathways of autophagy. This review mainly discusses the occurrence and development of autophagy, the selection of experimental models for HIRI, and the specific regulatory pathways of autophagy in HIRI. Autophagy has considerable potential in the treatment of HIRI.
肝缺血再灌注损伤（HIRI）是肝切除或肝移植的主要并发症，可严重影响患者预后。目前尚无针对HIRI的确切有效治疗策略。自噬是一种细胞内自我消化途径，启动该途径以清除受损细胞器和蛋白质，维持细胞存活、分化及内环境稳定。最近的研究表明，自噬参与HIRI的调控。众多药物和治疗方法可通过控制自噬途径改变HIRI的结局。本综述主要讨论自噬的发生发展、HIRI实验模型的选择以及自噬在HIRI中的具体调控途径。自噬在HIRI治疗中具有相当大的潜力。
